BACKGROUND: Recent studies have questioned the use of histamine (H2) receptor antagonist in stress ulcer prophylaxis because of an increased incidence of nosocomial pneumonia and subsequent death. DESIGN: This prospective randomized study compared prophylaxis with cimetidine vs sucralfate. SETTING: Medical/surgical intensive care unit in Springfield, Mass. PATIENTS: One hundred fourteen patients were enrolled. INTERVENTIONS:Cimetidine, administered as a primed continuous infusion using a 300-mg bolus followed by 37.5 mg/h, was compared with sucralfate, administered via nasogastric tube, at a dosage of 1 g every 6 hours suspended in 20 mL of sterile water. MAIN OUTCOME MEASURES: End points of the study included nosocomial pneumonia, gastrointestinal hemorrhage, and death. RESULTS:Fifty-six patients were randomized to receive cimetidine and their rate of pneumonia was 12.5%; upper gastrointestinal hemorrhage, 3.6%; and mortality, 33.9%. Fifty-eight patients were given sucralfate, and their rate of pneumonia was 13.8%; upper gastrointestinal hemorrhage, 3.4%; and mortality, 37.9%. There were no significant differences between these study end points. In patients who had pneumonia, 80% of isolates were aerobic gram-negative bacilli. CONCLUSIONS: These observations suggest that the rate of nosocomial pneumonia is not increased in patients in the intensive care unit who receive prophylaxis withcimetidine to prevent stress ulcer bleeding.
RCT Entities:
BACKGROUND: Recent studies have questioned the use of histamine (H2) receptor antagonist in stress ulcer prophylaxis because of an increased incidence of nosocomial pneumonia and subsequent death. DESIGN: This prospective randomized study compared prophylaxis with cimetidine vs sucralfate. SETTING: Medical/surgical intensive care unit in Springfield, Mass. PATIENTS: One hundred fourteen patients were enrolled. INTERVENTIONS:Cimetidine, administered as a primed continuous infusion using a 300-mg bolus followed by 37.5 mg/h, was compared with sucralfate, administered via nasogastric tube, at a dosage of 1 g every 6 hours suspended in 20 mL of sterile water. MAIN OUTCOME MEASURES: End points of the study included nosocomial pneumonia, gastrointestinal hemorrhage, and death. RESULTS: Fifty-six patients were randomized to receive cimetidine and their rate of pneumonia was 12.5%; upper gastrointestinal hemorrhage, 3.6%; and mortality, 33.9%. Fifty-eight patients were given sucralfate, and their rate of pneumonia was 13.8%; upper gastrointestinal hemorrhage, 3.4%; and mortality, 37.9%. There were no significant differences between these study end points. In patients who had pneumonia, 80% of isolates were aerobic gram-negative bacilli. CONCLUSIONS: These observations suggest that the rate of nosocomial pneumonia is not increased in patients in the intensive care unit who receive prophylaxis with cimetidine to prevent stress ulcer bleeding.
Authors: Ingrid Toews; Aneesh Thomas George; John V Peter; Richard Kirubakaran; Luís Eduardo S Fontes; Jabez Paul Barnabas Ezekiel; Joerg J Meerpohl Journal: Cochrane Database Syst Rev Date: 2018-06-04